SGLT2 inhibitor improves CV outcomes in severe heart failure
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020
The SGLT2 inhibitor empagliflozin is associated with a reduced risk of hospitalisation and death in patients who have heart failure with reduced ejection fraction (HFrEF), researchers have found.
Findings from the phase 3 EMPEROR-Reduced trial of 3700 patients with HFrEF show lower risk of CV mortality and hospitalisation in those taking 10mg a day of empagliflozin compared with placebo alongside their heart failure drugs.
The CV improvements were regardless of the presence of type 2 diabetes, the researchers, led by cardiologist Dr Milton Packer from the Baylor University Medical Center, in Dallas, Texas, US, told the European Cardiology Society virtual congress (ESC 2020).
